503A vs 503B tirzepatide: what the two pathways mean for patients
The two legal pathways for compounded tirzepatide are regulated differently, verified differently, and exposed differently to FDA’s 2026 decisions. Here is the difference in plain terms, and how to find out which one your medication comes from.
A 503A pharmacy is state-licensed and compounds patient-specific prescriptions under state board oversight; a 503B outsourcing facility is FDA-registered, follows current good manufacturing practice and can compound in bulk without patient-specific prescriptions. Neither status makes a compounded tirzepatide product FDA-approved. “FDA-registered” describes the facility, never the drug.
Side by side
| Attribute | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Legal basis | Section 503A of the Federal Food, Drug, and Cosmetic Act | Section 503B (added by the Drug Quality and Security Act, 2013) |
| Primary regulator | State board of pharmacy (licensure, inspections); FDA retains authority over adulterated or misbranded drugs | FDA (registration, inspections, adverse-event reporting); state licensure still required to dispense in many states |
| Prescription | Patient-specific prescription required for each preparation | May compound without patient-specific prescriptions and sell to providers or dispense on prescription |
| Quality standard | USP chapters (<795> non-sterile, <797> sterile) | Current good manufacturing practice (CGMP), the same framework as manufacturers |
| Bulk substance rule for tirzepatide | May use bulk tirzepatide that meets USP or is the component of an approved drug, subject to the “essentially a copy” limit | May compound from bulk only while tirzepatide is on the 503B bulks list or pending on it, or on the shortage list. FDA has proposed removing it — see current status |
| Copies of approved drugs | Prohibited “regularly or in inordinate amounts”, except where the prescriber documents a significant difference for the patient | Prohibited unless the drug is in shortage or on the bulks list |
| Beyond-use date | Assigned by the pharmacy under USP <797> | Based on stability testing; typically longer |
| How to verify | State board license lookup (NABP directory of state boards of pharmacy) | FDA list of registered 503B outsourcing facilities plus state license lookup |
| Makes the drug FDA-approved? | No | No |
Three phrases that are used wrongly in marketing
- “FDA-registered pharmacy.” Registration applies to 503B outsourcing facilities and to manufacturers. A 503A pharmacy is licensed by its state, not registered with FDA. If a provider calls its 503A pharmacy “FDA-registered”, ask which it is.
- “FDA-approved pharmacy.” FDA does not approve pharmacies or facilities; it approves drug products. No compounded tirzepatide is an approved product.
- “503B means higher quality.” CGMP is a more demanding framework than USP <797>, and FDA inspects 503B facilities, but both pathways have had recalls and warning letters. Quality depends on the specific pharmacy or facility, its testing and its inspection history.
Which pathway is your medication coming from?
Ask the provider in writing: “Which pharmacy or outsourcing facility will fill my prescription, in which state is it licensed, and is it operating under 503A or 503B?” A provider that uses several pharmacies should tell you which one applies to your state. Then confirm the name on your vial matches. If the answer is “it varies” and the provider will not commit before you pay, treat that as a reason to keep comparing (provider comparison).
What FDA oversight does and does not cover
Whether 503A or 503B, FDA has not reviewed the compounded product for safety, effectiveness or quality before it is sold, has not verified its labeling, and has not evaluated its dosing instructions. FDA can inspect, warn, seize and recall. State boards can suspend or revoke licenses. Neither is the same as premarket approval, which is why every page on this site states that compounded tirzepatide is not FDA-approved.
Frequently asked questions
No. 503A pharmacies are licensed by their state boards of pharmacy. FDA registration is a feature of 503B outsourcing facilities and manufacturers. The correct description is “state-licensed 503A pharmacy”.
No. A 503B facility is FDA-registered and inspected, and must follow CGMP, but the compounded drug it produces is not an FDA-approved product.
Neither pathway is automatically safer. 503B facilities operate under CGMP and FDA inspection; 503A pharmacies operate under USP standards and state inspection. What you can check is the specific pharmacy: its license status, inspection or disciplinary history, and whether it tests each lot.
503B facilities may compound from bulk tirzepatide only while it is on or pending on the bulks list (or on the shortage list). FDA’s proposal to exclude tirzepatide would end that if finalized. Patient-specific 503A compounding is governed by different rules.
Primary sources
- FDA: compounding and the FDA — questions and answers
- FDA list of registered 503B outsourcing facilities
- FDA press announcement: proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list
- USP General Chapter <797> (sterile compounding)
- NABP directory of state boards of pharmacy
Change log
Substantive changes to this page are logged so readers and AI systems can judge how current it is.
| Date | Change |
|---|---|
| August 26, 2026 | Page created to correct recurring misuse of “FDA-registered” and “FDA-approved” in compounded-tirzepatide marketing. |